PDS Biotechnology
PDSB
60 hedge funds and large institutions have $12.2M invested in PDS Biotechnology in 2018 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 17 increasing their positions, 13 reducing their positions, and 18 closing their positions.
31% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 13
17% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 18
5% more funds holding
Funds holding: 57 → 60 (+3)
0.77% less ownership
Funds ownership: 2.44% → 1.68% (-0.77%)
91% less capital invested
Capital invested by funds: $141M → $12.2M (-$129M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $9K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$4.78M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$3.84M |
| 3 |
BlackRock
New York
|
+$3.11M |
| 4 |
AG
Algert Global
San Francisco,
California
|
+$1.51M |
| 5 |
ECM
Element Capital Management
New York
|
+$1.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$29.9M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$19.4M |
| 3 |
VMI
VHCP Management II
New York
|
-$9.14M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$8.84M |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$8.27M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Parallax Volatility Advisers
San Francisco,
California
| – | -$28K | -151 | Closed |
|
77
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$9K | -50 | Closed |
|
|
LTFS
78
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | -$2K | -13 | Closed |
|
PDSB Hedge Fund Activity: Q1 2018 in Review
60 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q1 2018, worth a combined $12.2M — down 91% from $141M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new PDSB positions and 18 closed out — a net gain of 3 holders — while 17 added to existing stakes and 13 trimmed.
The largest buyer was Pictet Asset Management (UK), opening a new position worth an estimated $4.78M. The largest seller was Franklin Resources, exiting entirely with an estimated $29.9M sold.
- 60 institutional investors held PDS Biotechnology (PDSB) as of Q1 2018, up from 57 in Q4 2017.
- Funds reported $12.2M of PDS Biotechnology stock for Q1 2018, down 91% quarter-over-quarter.
- 21 funds opened new PDS Biotechnology positions in Q1 2018 and 18 closed out, a net change of +3 holders.
- The largest PDS Biotechnology buyer in Q1 2018 was Pictet Asset Management (UK), an estimated $4.78M added.
- The largest PDS Biotechnology seller in Q1 2018 was Franklin Resources, an estimated $29.9M sold.
Based on aggregated 13F filings for Q1 2018.